查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715781

患者来源异质骨移植/PDX 模型市场（按类型、肿瘤类型、研究类型、植入方法、应用和最终用户划分）—2025 年至 2030 年全球预测

Patient-Derived Xenograft/PDX Model Market by Type, Tumor Type, Study Type, Implantation Method, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023 年病患来源异质骨移植/PDX 模型市场价值为 3.8338 亿美元，预计 2024 年将成长至 4.2904 亿美元，复合年增长率为 12.27%，预计到 2030 年将达到 8.6231 亿美元。

主要市场统计数据
基准年2023年 3.8338亿美元
预计2024年 4.2904亿美元
预测年份 2030 8.6231亿美元
复合年增长率（%） 12.27%

患者来源的异种移植模型领域的不断发展深刻地改变了临床前研究和药物开发的范式。这种将人类肿瘤组织移植到免疫力缺乏动物体内的创新方法已迅速发展成为转化肿瘤学的重要工具。该技术模拟人类肿瘤微环境的能力越来越强，因此被认为提供了评估治疗效果和抗药性的宝贵平台。随着全球趋势日益转向个人化医疗，PDX 模型不仅减轻了传统体外系统的局限性，也为更深入了解癌症复杂的生物学铺平了道路。本报告探讨了推动 PDX 模型在一系列应用中采用的历史背景、基础科学和市场动态。我们的深入分析将严谨的科学研究与市场洞察相结合，帮助读者理解 PDX 模型的复杂细微差别。综合研究数据和分析框架的整合使专家和决策者对现有的挑战和新兴机会有了深入的了解，为这一变革性的生物医学研究领域的持续创新和投资奠定了基础。

改变病患来源的异质骨移植/PDX 模型市场

近年来，技术创新、不断发展的法律规范以及对更具预测性的临床前测试模型的稳定需求，导致了 PDX 模型市场发生了变革性的变化。这种转变源于人们越来越认识到基于传统细胞株的模型的缺点，以及对忠实重现人类肿瘤生物学的系统的迫切需求。基因工程和成像技术的进步进一步提高了 PDX 研究的精确度和可重复性，使学术界和工业界的研究人员能够克服复杂的肿瘤学挑战。

市场参与者正在利用将高级数据分析与即时监控相结合的整合平台，为治疗反应提供前所未有的见解。重点是简化实验工作流程，以减少週转时间和成本，从而促进对新癌症类型和治疗方法的敏捷反应。随着研究人员不断努力根据患者的个别情况量身定制治疗方法，市场正在大力转向个人化医疗。这种转变不仅要求临床前评估更加精确，而且需要研究机构、生技公司和监管机构之间加强合作，最终为癌症研究和药物开发树立新的标准。

全面的关键细分市场洞察

PDX 模型市场的细分揭示了清晰的模式，为当前行业趋势提供了可行的见解。基于类型的分析区分了小鼠和大鼠模型，突出了与每种动物系统相关的细微差别和特定优势。透过肿瘤类型的视角，可以研究多种癌症，包括胃肠道癌症、妇科癌症、血液癌症、呼吸系统癌症和泌尿系统癌症，解决临床表现中固有的异质性。调查方法细分包括体外、体内和体内方法，每种方法在模拟人类生物反应方面都有独特的优势。此外，根据植入方法区分模型突显了异位、原位和皮下方法在提高实验结果的有效性和精确度方面的重要性。

市场内的应用同样多样化，涵盖基础癌症研究、生物标记发现、基因组和分子研究、个人化医疗、临床前药物评估和肿瘤微环境分析。学术研究机构、癌症研究中心以及製药和生物技术公司在这些模型的测试、检验和最终临床转化中发挥重要作用。这种多面向的细分方法凸显了这个动态领域的研究界的专业知识深度和互联互通性。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 癌症发生率上升推动了对先进临床前模型的需求，以促进药物研发
      • 增加政府对肿瘤学研究的投入与资金
      • 将PDX模型引入精准医疗，改善病患预后
    • 限制因素
      • 对 PDX 模型的不稳定性及高成本影响的担忧
    • 机会
      • 策略合作与伙伴关係加速抗癌药物研发
      • 在药物测试中整合先进的分析平台和PDX模型
    • 任务
      • 限制在研究中使用病人来源异种移植模型的伦理问题和法规
  • 市场区隔分析
    • 类型：遗传相似性增强了小鼠模型在转化肿瘤学研究中的作用
    • 肿瘤类型：PDX 模型在血液系统癌症中的应用越来越广泛，因为它们可以在基因和表型上紧密模拟人类疾病。
    • 研究类型：透过准确重现人类肿瘤生物学，增强临床前癌症研究的体内模型
    • 植入方法：皮下植入因其在研究环境中的简单性和实用性而被越来越多地采用。
    • 应用：PDX 模型透过精确的癌症模拟促进临床前药物评估
    • 最终用户：製药和生物技术公司利用患者来源的异种移植/PDX 模型推动药物开发的创新
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 病患来源异质骨移植/PDX 模型市场（按类型）

  • 小鼠模型
  • 大鼠模型

7. 病人异质骨移植/PDX 模型市场（依肿瘤类型）

  • 胃肠道
  • 妇科
  • 血液学
  • 呼吸系统
  • 泌尿系统

8. 病人异质骨移植/PDX 模型市场研究（按类型）

  • 体外
  • 体外
  • 体内

9. 病人来源异质骨移植/PDX 模型市场（依移植方法）

  • 异位
  • 原位
  • 皮下

第 10 章 患者异质骨移植/PDX 模型市场（按应用）

  • 基金会癌症研究
  • 生物标记发现
  • 基因组和分子研究
  • 个人化医疗
  • 临床前药物评价
  • 肿瘤微环境分析

第 11 章 病患异质骨移植/PDX 模型市场（依最终使用者）

  • 学术研究所
  • 癌症研究中心
  • 製药和生物技术公司

12. 美洲患者异质骨移植/PDX 模型市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区病患来源异质骨移植移植/PDX 模型市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲病患来源异质骨移植/PDX 模型市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abnova Corporation
  • Altogen Labs
  • Biocytogen
  • BioDuro LLC
  • BioReperia AB
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Animodel
  • Creative Biolabs
  • Crown Bioscience by JSR Corporation
  • EPO Berlin-Buch GmbH
  • GemPharmatech Co. Ltd.
  • Genesis Drug Discovery & Development
  • Hera Biolabs
  • HOIST Co.,Ltd.
  • InnoSer
  • Inotiv, Inc.
  • Laboratory Corporation of America Holdings
  • LIDE Shanghai Biotech, Ltd
  • Mediford Corporation by PHC Holdings Corporation
  • Oncodesign Services
  • Shanghai ChemPartner
  • Shanghai Medicilon Inc.
  • TheraIndx Lifesciences Pvt. Ltd.
  • Urosphere SAS
  • WuXi AppTec Co., Ltd.
  • Xentech
Product Code: MRR-FF1601152744

The Patient-Derived Xenograft/PDX Model Market was valued at USD 383.38 million in 2023 and is projected to grow to USD 429.04 million in 2024, with a CAGR of 12.27%, reaching USD 862.31 million by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 383.38 million
Estimated Year [2024] USD 429.04 million
Forecast Year [2030] USD 862.31 million
CAGR (%) 12.27%

The evolving field of patient-derived xenograft models has significantly reshaped preclinical research and drug development paradigms. This innovative approach, which involves implanting human tumor tissues into immunocompromised animals, has swiftly developed into a vital tool for translational oncology. The methodology is gaining respect for its enhanced ability to mimic the human tumor microenvironment, thereby providing an invaluable platform for evaluating therapeutic efficacy and drug resistance. As global healthcare trends increasingly shift towards personalized medicine, PDX models not only mitigate the limitations of traditional in vitro systems but also pave the way for deeper insights into complex cancer biology. This report explores the historical context, underlying science, and market dynamics that continue to drive the adoption of these models across a range of applications. Detailed analyses that blend rigorous scientific inquiry with market trend insights guide readers through the intricate nuances of PDX models. The integration of comprehensive research data and analytical frameworks provides experts and decision-makers with a robust understanding of existing challenges and emerging opportunities, setting the stage for continued innovation and investment in this transformative area of biomedical research.

Transformative Shifts in the PDX Model Market Landscape

Recent years have seen transformative shifts in the PDX model market driven by technological innovation, evolving regulatory frameworks, and the steady demand for more predictive preclinical testing models. This transformation is rooted in the increasing recognition of the shortcomings of conventional cell-line based models and the compelling need for systems that closely replicate human tumor biology. Progressive advancements in genetic engineering and imaging technologies have further bolstered the precision and reproducibility of PDX studies, ensuring that both academic and industrial research avenues are well-equipped to navigate complex oncology challenges.

Market players are capitalizing on integrated platforms that combine advanced data analytics with real-time monitoring, offering unprecedented insights into therapeutic responses. There is a pronounced emphasis on streamlining experimental workflows to reduce turnaround time and cost, which in turn fosters a more agile response to emerging cancer types and treatment modalities. As researchers continually strive to tailor therapies to individual patient profiles, the market is experiencing a profound pivot towards personalized medicine. This shift not only demands higher accuracy in preclinical evaluation but also necessitates robust collaboration between research institutions, biotechnology companies, and regulatory bodies, ultimately setting a new standard for cancer research and drug development.

Comprehensive Key Segmentation Insights

The segmentation of the PDX model market reveals distinct patterns that offer actionable insights into current industry trends. An analysis based on type differentiates between mice models and rat models, highlighting the nuances and specific advantages associated with each animal system. When viewed through the lens of tumor type, research encompasses a diverse range that includes gastrointestinal, gynecological, hematological, respiratory, and urological cancers, thereby addressing the heterogeneity inherent in clinical presentations. The study type segmentation covers ex-vivo, in-vitro, and in-vivo methodologies, each providing unique strengths when it comes to simulating human biological responses. Furthermore, distinguishing models based on the implantation method shows the importance of heterotopic, orthotopic, and subcutaneous approaches in refining the relevance and accuracy of experimental outcomes.

Applications within the market are equally diverse, spanning basic cancer research, biomarker discovery, genomic and molecular studies, personalized medicine, preclinical drug evaluation, and tumor microenvironment analysis. End-user segmentation adds another important layer of insight, with academic research institutes, cancer research centers, and pharmaceutical and biotechnology companies each playing critical roles in the testing, validation, and eventual clinical translation of these models. Such a multifaceted segmentation approach underscores the depth of specialization and the interconnected nature of the research community in this dynamic field.

Based on Type, market is studied across Mice Models and Rat Models.

Based on Tumor Type, market is studied across Gastrointestinal, Gynecological, Hematological, Respiratory, and Urological.

Based on Study Type, market is studied across Ex-vivo, In-vitro, and In-vivo.

Based on Implantation Method, market is studied across Heterotopic, Orthotopic, and Subcutaneous.

Based on Application, market is studied across Basic Cancer Research, Biomarker Discovery, Genomic & Molecular Studies, Personalized Medicine, Preclinical Drug Evaluation, and Tumor Microenvironment Analysis.

Based on End-User, market is studied across Academic Research Institutes, Cancer Research Centers, and Pharmaceutical & Biotechnology Companies.

Regional Insights Supporting Global Market Trends

Geographical analysis of the PDX model market illustrates a robust, multi-regional growth narrative with significant contributions emerging from several key territories. In the Americas, robust investment in biomedical research infrastructure and supportive governmental policies continue to drive advancements. Meanwhile, regions encompassing Europe, the Middle East and Africa are increasingly prioritizing translational research, with a greater alignment towards personalized treatment approaches and more stringent regulatory oversight supporting higher quality preclinical evaluations. Asia-Pacific stands out as a vibrant hub of innovation, supported by substantial investment in biotechnology and an expanding base of both clinical and academic research institutions. The convergence of these regional dynamics not only creates a fertile ground for collaborative research but also reinforces global standards through data sharing and cross-border partnerships.

Collectively, these regional insights point to a future where market expansion will be bolstered by a unified approach to research excellence. The confluence of diverse regional capabilities ensures that the benefits of PDX models are realized on a global scale, thereby supporting a more integrated and responsive healthcare system worldwide.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insightful Analysis of Leading Market Players

The competitive landscape in the PDX market is defined by a robust roster of companies that continue to push the boundaries of preclinical research and drug development. Key market players include Abnova Corporation, Altogen Labs, Biocytogen, BioDuro LLC, BioReperia AB, Certis Oncology Solutions, Champions Oncology, Inc., Charles River Laboratories International, Inc., Creative Animodel, Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPharmatech Co. Ltd., Genesis Drug Discovery & Development, Hera Biolabs, HOIST Co.,Ltd., InnoSer, Inotiv, Inc., Laboratory Corporation of America Holdings, LIDE Shanghai Biotech, Ltd, Mediford Corporation by PHC Holdings Corporation, Oncodesign Services, Shanghai ChemPartner, Shanghai Medicilon Inc., TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and Xentech.

These organizations have strategically capitalized on technological innovations and deep scientific expertise to address an increasingly competitive market environment. Their ongoing investments in research and development, persistent focus on quality and scalability, and commitment to forging strategic collaborations have been pivotal in expanding their respective portfolios. By maintaining a forward-thinking approach, these leaders ensure that their platforms remain at the cutting edge, thereby contributing significantly to the evolution of preclinical cancer research. Their efforts not only drive market growth but also inspire emerging players to adopt more rigorous standards in the pursuit of clinical excellence.

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Biocytogen, BioDuro LLC, BioReperia AB, Certis Oncology Solutions, Champions Oncology, Inc., Charles River Laboratories International, Inc., Creative Animodel, Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPharmatech Co. Ltd., Genesis Drug Discovery & Development, Hera Biolabs, HOIST Co.,Ltd., InnoSer, Inotiv, Inc., Laboratory Corporation of America Holdings, LIDE Shanghai Biotech, Ltd, Mediford Corporation by PHC Holdings Corporation, Oncodesign Services, Shanghai ChemPartner, Shanghai Medicilon Inc., TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and Xentech. Actionable Recommendations for Industry Leaders

For industry leaders looking to harness the potential of PDX models, several actionable strategies emerge from current market trends. Optimizing research pipelines by investing in state-of-the-art imaging, genetic profiling, and data integration tools can significantly enhance preclinical validation and streamline drug development processes. Enhancing collaborative networks with leading academic institutions and clinical research centers will also be crucial in accessing real-world insights and accelerating translational research.

It is recommended that companies invest in robust quality control measures and standardization protocols to increase the reproducibility and reliability of their models. Broadening the spectrum of tumor types and refining implantation methodologies can further boost the clinical relevance of studies, thereby offering more targeted insights for personalized medicine initiatives. Leaders should also consider strategic partnerships and joint ventures as pivotal avenues for expanding their technological capabilities and accessing untapped markets. Finally, a dedicated focus on regulatory intelligence will enable organizations to navigate evolving legal frameworks more effectively, ensuring seamless integration of innovative approaches within established clinical paradigms.

Conclusion and Forward-Looking Perspective

In summing up, the landscape of patient-derived xenograft models represents a transformative and dynamic segment within the broader realm of oncology research and drug development. The integration of advanced biological models with cutting-edge technologies has paved the way for an era where preclinical assessments are more predictive and clinically relevant than ever before. This evolution not only underscores the importance of PDX models as a cornerstone for modern cancer research but also points to a future marked by enhanced precision, greater personalization, and more rapid translational outcomes.

As the market continues to evolve, stakeholders across academia, industry, and regulatory agencies must embrace the opportunities born of this convergence. A concerted effort in addressing experimental challenges, fine-tuning methodological approaches, and fostering strategic research partnerships will be key to unlocking further advancements. The journey ahead promises exciting developments, laying a robust foundation for innovations that are set to redefine therapeutic paradigms and ultimately improve patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in cancer prevalence amplifying the need for advanced preclinical models to enhance drug discovery
      • 5.1.1.2. Increased government initiatives and fundings for oncology research
      • 5.1.1.3. Incorporation of PDX models in precision medicine for enhanced patient outcomes
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with instability and high-cost implications of PDX models
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic collaborations and partnership to accelerate cancer drug development
      • 5.1.3.2. Integration of advanced analytical platforms with PDX models in drug testing
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical concerns and regulations limiting the use of patient-derived xenograft models in research
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Genetic similarity enhances mice model's role in translational oncology research
    • 5.2.2. Tumor Type: The ability of PDX models to closely mimic the human disease in genetic and phenotypic aspects increases the usage in hematological cancers
    • 5.2.3. Study Type: In-vivo Models enhancing preclinical cancer research through accurate replication of human tumor biology
    • 5.2.4. Implantation Method: The increasing adoption of subcutaneous implantation is driven by its simplicity and practicality in research settings
    • 5.2.5. Application: PDX models advancing preclinical drug evaluation with accurate cancer simulation
    • 5.2.6. End-User: Driving innovation in drug development with Patient-Derived Xenograft/PDX models in pharmaceutical and biotechnology companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Patient-Derived Xenograft/PDX Model Market, by Type

  • 6.1. Introduction
  • 6.2. Mice Models
  • 6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

  • 7.1. Introduction
  • 7.2. Gastrointestinal
  • 7.3. Gynecological
  • 7.4. Hematological
  • 7.5. Respiratory
  • 7.6. Urological

8. Patient-Derived Xenograft/PDX Model Market, by Study Type

  • 8.1. Introduction
  • 8.2. Ex-vivo
  • 8.3. In-vitro
  • 8.4. In-vivo

9. Patient-Derived Xenograft/PDX Model Market, by Implantation Method

  • 9.1. Introduction
  • 9.2. Heterotopic
  • 9.3. Orthotopic
  • 9.4. Subcutaneous

10. Patient-Derived Xenograft/PDX Model Market, by Application

  • 10.1. Introduction
  • 10.2. Basic Cancer Research
  • 10.3. Biomarker Discovery
  • 10.4. Genomic & Molecular Studies
  • 10.5. Personalized Medicine
  • 10.6. Preclinical Drug Evaluation
  • 10.7. Tumor Microenvironment Analysis

11. Patient-Derived Xenograft/PDX Model Market, by End-User

  • 11.1. Introduction
  • 11.2. Academic Research Institutes
  • 11.3. Cancer Research Centers
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Americas Patient-Derived Xenograft/PDX Model Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Certis Oncology unveils AI-driven chatbot to enhance cancer research insights and PDX model efficiency
    • 15.3.2. UCLB and CancerTools.org partnership enhances new NSCLC PDX models development
    • 15.3.3. Champions Oncology announces licensing agreement with Weill Cornell Medicine
    • 15.3.4. REM-422 demonstrates tumor regression in ACC PDX models at 2024 symposium
    • 15.3.5. Charles River Laboratories transforming oncology research with PDX models and digital twins at AACR 2024
    • 15.3.6. Crown Bioscience has announced new preclinical and translational oncology data at the AACR 2024
    • 15.3.7. ProteinQure unveils breakthrough PDC showcasing exceptional efficacy in diverse PDX models
    • 15.3.8. InVivo Biosystems and BioReperia partners to transform cancer drug development
    • 15.3.9. Kiyatec and XenoSTART collaborated to help reduce drug development costs
    • 15.3.10. Soteria Precision Medicine Foundation partners with Certis Oncology Solutions
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. WuXi AppTec Co., Ltd.
    • 15.4.2. Crown Bioscience by JSR Corporation
    • 15.4.3. Mediford Corporation by PHC Holdings Corporation
    • 15.4.4. Charles River Laboratories International, Inc.

Companies Mentioned

  • 1. Abnova Corporation
  • 2. Altogen Labs
  • 3. Biocytogen
  • 4. BioDuro LLC
  • 5. BioReperia AB
  • 6. Certis Oncology Solutions
  • 7. Champions Oncology, Inc.
  • 8. Charles River Laboratories International, Inc.
  • 9. Creative Animodel
  • 10. Creative Biolabs
  • 11. Crown Bioscience by JSR Corporation
  • 12. EPO Berlin-Buch GmbH
  • 13. GemPharmatech Co. Ltd.
  • 14. Genesis Drug Discovery & Development
  • 15. Hera Biolabs
  • 16. HOIST Co.,Ltd.
  • 17. InnoSer
  • 18. Inotiv, Inc.
  • 19. Laboratory Corporation of America Holdings
  • 20. LIDE Shanghai Biotech, Ltd
  • 21. Mediford Corporation by PHC Holdings Corporation
  • 22. Oncodesign Services
  • 23. Shanghai ChemPartner
  • 24. Shanghai Medicilon Inc.
  • 25. TheraIndx Lifesciences Pvt. Ltd.
  • 26. Urosphere SAS
  • 27. WuXi AppTec Co., Ltd.
  • 28. Xentech

LIST OF FIGURES

  • FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET MULTI-CURRENCY
  • FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET MULTI-LANGUAGE
  • FIGURE 3. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
  • FIGURE 4. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
  • TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023